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ABSTRACT 
 
Opportunistic fungal infections have become problematic in recent years. There has been an 
emergence of new fungal pathogens, development of antifungal resistance, and increasing 
prevalence. In addition, toxicity, resistance, and lack of efficacy as a single agent limit the 
effectiveness of current antifungal drugs. Therefore, new drugs targeting new pathways are 
greatly needed. An analog derived from the marine natural product phloeodictine, analog PHL5-
34A, was identified as having strong in vitro antifungal activity. In this study, its mechanism of 
action (MOA) was investigated in the model yeast, Saccharomyces cerevisiae.  This study made 
use of a collection of 166 yeast mutants carrying deletions in transcription factors, which 
function as master regulators of cellular processes. Using the parent S. cerevisiae strain BY4742, 
a pilot experiment was conducted to determine the sub-inhibitory concentration of PHL5-34A 
that reduced cell growth on agar plates. After assay conditions were optimized, the mutant 
collection was screened to identify mutants with altered sensitivity to PHL5-34A. Of the 166 
deletion mutants tested, 20 were found to be hypersensitive to PHL5-34A when compared to 
the parent. Drop-test assays were conducted and 10 mutants were confirmed to be 
hypersensitive to PHL5-34A. Of these confirmed mutants, 4 mutants were found to carry 
deletions in genes required for cell cycle functions. These 4 mutations were then analyzed by 
PCR to confirm that they were in the correct genes.  This work has demonstrated that the cell 
cycle is one of the pathways affected by PHL5-34A, and it will serve as an important step in 
determining the exact MOA of this compound.  
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INTRODUCTION 
  
Opportunistic fungal infections have become problematic in recent years. There has 
been an emergence of new fungal pathogens, development of antifungal resistance, and 
increasing prevalence.  In addition, toxicity, resistance, and lack of efficacy as a single 
agent limit the effectiveness of current antifungal drugs.  High rates of morbidity and 
mortality continue to be associated with infections that are caused by molds and yeast 
(Mohr et al., 2008). The advancement in medicine, surgery, and transplantology in the 
last three decades has caused an alarming increase in immunocompromised patients 
that are susceptible to fungal infections. Many patients are at a higher risk of developing 
mycoses, such as those suffering from HIV infection, receiving organ transplantation and 
intensive cancer therapy (Karkowska-Kuleta et al., 2009). With such a wide range of risk 
factors, the prophylactic use of antifungal therapies is one of the reasons of frequent 
resistance to antifungal drugs. This introductory section provides background 
information on the major fungal pathogens, the current antifungal agents, the value of 
mechanism for action studies, and the novel antifungal compound, PHL5-34A that was 
studied in this project. 
 
Major fungal pathogens. Candida species are the most common pathogens associated 
with fungal disease, and Aspergillus, Cryptococcus sp and Zygomycetes account for 
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many fungal infections as well (Mohr et al., 2008). These fungi are very common and can 
be acquired from host surroundings. After antifungal treatment, the mortality rate is still 
very high due to the patient’s immunodeficiency, late diagnosis, or fungal drug 
resistance (Karkowska-Kuleta et al., 2009).  
 
There are many invasive infections associated with Candida species, from catheter-
associated localized infections to widespread disseminated disease (Mohr et al., 2008). 
There are currently more than two hundred ascomycetous yeasts included in the genus 
Candida, and of these, only a few species of the genus are opportunistic pathogens of 
humans. Candida albicans are thought to be the most common cause of fungal 
infections in humans today (Karkowska-Kuleta et al., 2009).  Identifying patients that are 
at a higher risk of developing Candida infections is an important step in determining 
which patients should receive treatment.  Some of the treatment options may include 
strategies that are presumptive (there are many risk factors that raise suspicion of 
infection) or prophylactic (preventative measure for high-risk factors).  Some of the 
most common risk factors that have been identified for invasive candidiasis are 
prolonged stay in the intensive care unit (ICU), placement of central venous catheters, 
prolonged treatment with broad-spectrum antibiotics, receipt of parenteral nutrition, 
recent surgery (particularly intraabdominal), hemodialysis, and a diagnosis of diabetes 
mellitus or pancreatitis (Mohr et al., 2008).  
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Aspergillus fumigatus, is an ascomycetous fungus found around the world and its spores 
are abundant in the environment due to their small size.  A. fumigatus conidia are 
frequently present in food, tap water, at home, and in office rooms (Karkowska-Kuleta 
et al., 2009).  A definitive diagnosis of invasive aspergillosis requires a positive culture 
from a sterile site, or it requires histologic or radiologic evidence in a patient at high risk 
with compatible clinical findings.   Unfortunately, when the fungi are positively 
identified in the body, it could be too late for treatment. Techniques for an early 
diagnosis, preventative strategies, and new treatment methods are needed to reduce 
the mortality in invasive aspergillosis patients (Mohr et al., 2008). 
 
Cryptococcus neoformans is a saprophytic, basidiomycetous, dimorphic organism found 
worldwide. Its natural habitats are pigeon droppings and contaminated soil, and its 
small basidiospores can turn into yeast cells. The basidiospores or yeast cells may be 
inhaled by humans, then through the respiratory tract the pathogen can disseminate 
within the host causing pulmonary infections, and subsequently, due to the predilection 
of C. neoformans for the central nervous system, life threatening meningoencephalitis 
(Karkowska-Kuleta et al., 2009).  It causes infections in both immunocompromised and 
immunocompetent patients. In addition, patients who have undergone organ 
transplantation and are receiving high-dose corticosteroids are at increased risk for 
development of cryptococcosis (Karkowska-Kuleta et al., 2009).  
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Current antifungal agents. There are currently five classes of antifungal agents that are 
used orally or intravenously for the treatment of fungal infections in humans.  The five 
classes are polyenes, pyrimidine analogues, allylamines, azoles and echinocandins (Table 
1).  These five classes of antifungal agents each have limitations that go along with their 
advantages.  Some of the limitations include spectrum of activity, route of 
administration, drug interactions, and toxicity profile (Denning and Hope, 2010). The cell 
membrane, DNA and RNA synthesis, and the cell wall are the three main targets of 
drugs that are in current use for systemic therapy of invasive mycoses. The polyenes and 
azoles target the cell membrane, the antimetabolite 5-fluorocytosine interferes with 
DNA and RNA synthesis, and echinocandins affect the cell wall (Nosanchuk, 2006).  
 
The bacterial genus Streptomyces noursei produce polyenes, which are broad spectrum 
antifungal agents.  There have been approximately ninety polyenes discovered since the 
1950’s, but problems with solubility, stability, oral bioavailability, and toxicity have 
prevented many of these compounds from being developed for clinical purposes 
(Denning and Hope, 2010).  Amphotericin B is the polyene primarily in use 
therapeutically.  Amphotericin B is a product of Streptomyces nodosus. Amphotericin B 
selectively and irreversibly binds fungal cell membrane sterols.  The interaction of the 
antifungal with membrane sterols results in the formation of transmembrane pores, 
allowing for the leakage of ions and small molecules resulting in cellular damage or 
death.  The major drawbacks for amphotericin B use are its significant side effects and 
that intravenous administration is required for treatment of invasive mycoses.  
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Significant toxicities include fever, chills, arrhythmia, hypotension, respiratory distress, 
type IV renal tubular acidosis, renal failure, and anemia (Denning and Hope, 2010).  
 
Azoles are the second class to target the cell membrane of fungi. The major groups of 
azoles are the imidazoles and the triazoles. These two groups have five-membered 
organic rings containing either two or three nitrogen molecules. Cellular and 
mitochondrial membranes are both affected by azoles. The azoles inhibit cytochrome 
P450-dependent 14α-lanosterol demethylation, which is a critical step in the synthesis 
of ergosterol, an important component of fungal membranes (Denning and Hope, 2010). 
The mode of administration is different in imidazoles and triazoles. Imidazoles are used 
by topical treatment while triazoles can be administered intravenously and orally. Since 
the azoles affect the P450 enzyme activity, their main toxicities are due to interactions 
with other compounds that induce or inhibit this system (Denning and Hope, 2010).  
Since the azoles are fungistatic drugs, their widespread use has resulted in the 
development of drug resistance (Sanglard, 2002). 
 
Flucytosine is a pyrimidine analogue, and it has been available since 1972. Flucytosine is 
the only antimetabolite available for the treatment of systemic fungal infections 
(Denning and Hope, 2010). Flucytosine is a fluorine analogue of cytosine that functions 
as an inhibitor of thymidylate synthetase. It is only efficacious when administered in 
combination with amphotericin B. The major toxicity problems for flucytosine include 
bone marrow suppression, myocardial suppression, myocardial toxicity, and renal 
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failure. The spectrum of activity is rather limited with flucytosine, but it is active in 
Candida spp., C. neoformans, and some black molds (Denning and Hope, 2010).  
 
The only allylamine in clinical use today is terbinafine. Terbinafine was discovered as a 
derivative of the topical antifungal naftifine, which was the original compound of the 
allylamine class (Denning and Hope, 2010). Terbinafine has limited activity for treatment 
of invasive fungal diseases, and is mainly effective against fungi such as dermatophytes.  
It can be combined with voriconazole for treatment of infections caused by 
Scedosporium prolificans (Denning and Hope, 2010). 
 
The echinocandins are the newest agents clinically available for use. They are water-
soluble large amphipathic polypeptides that are only available in intravenous forms. The 
drugs inhibit 1,3-β-glucan, the major glucan in many fungi (Denning and Hope, 2010). 
Organisms such as C. neoformans, which have mainly 1,6-β-glucan and α-glucans, are 
resistant. The major toxicities with this include drug interactions, phlebitis, and fever 
(Denning and Hope, 2010).  
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Mechanism of action studies on new antifungal compounds.  As described above, the 
antifungal drugs that are being used today have several limitations including toxicity, 
resistance, lack of efficacy as a single agent, a limited spectrum of activity, and high cost.  
In addition, their targets are mainly restricted to the cell membrane and cell wall.  
Therefore, the need for new drugs targeting new pathways is greater than ever.  The 
identification of the molecular targets of new antifungal drugs and understanding how 
these drugs work in fungal cells is important in the antifungal drug discovery process 
(Agarwal et al., 2008).  Compounds that have a distinct mechanism of action (MOA) are 
at a higher demand because they can be used for combinatorial or chemical 
modifications.  It is also important to determine whether a novel antifungal drug is 
inhibiting a pathway that is targeted by currently available drugs or if it is targeting a 
Class and 
Compound 
Target Spectrum Limitations 
Polyene 
antibiotics 
Amphotericin 
B 
Lipid 
formulation 
of 
amphotericin 
B 
 
Cell membrane  
(interaction with ergosterol, increased 
membrane permeability) 
 
Broad spectrum against most invasive 
fungal infections 
 
  Nephrotoxicity 
  High cost of lipid formulations 
Nucleoside 
analog 
Flucytosine 
 
DNA, RNA synthesis 
 
Candida spp., Cryptococcus spp.,  and 
some filamentous species 
 
  Not very effective alone 
  Resistance problems 
Antifungal 
azoles 
Fluconazole 
 
 
Cell membrane 
(ergosterol biosynthesis) 
 
Candida spp., Cryptococcus spp., and 
some filamentous species 
 
  Narrow spectrum 
  Resistance problems 
Allylamines 
Terbinafine 
 
Cell membrane 
(ergosterol biosynthesis) 
 
Dermatophytes  
 
  Useful only in fungal nail infections 
 Not of use in invasive infection 
Echinocandins 
Caspofungin 
 
 
Cell wall 
[-(1,3)glucan synthase] 
 
Candida spp including azole-resistant 
species, and some filamentous species 
 
  Modest efficacy as first line agent 
 Narrow spectrum 
Table 1: Currently Available Antifungal Agents 
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new pathway.  If a compound inhibits a novel pathway, it can serve as a useful tool for 
further exploring the targeted biological pathway and understanding its regulation.  
When testing a novel antifungal compound, it is also important to predict the toxic 
effects of the compound early in drug development.   Finally, identifying pathways that 
lead to drug resistance, which are sometimes related to the MOA of a drug, would 
provide further information useful to the drug discovery process. 
 
PHL5-34A, a novel antifungal compound.  PHL5-34A is a novel marine compound that 
was studied in this project. PHL5-34A is a synthetic compound based on the 
phloeodictine class of compounds found in marine sponges such as Pellina eusiphonia 
(Li et al., 2011).  These compounds have a bicyclic tetrahyropyrrolopyrimidinium core 
with an aliphatic side chain at C-6 (Figure 1).  A novel analog of one of these compounds, 
PHL5-34A was synthesized chemically at the National Center for Natural Products 
Research at the University of Mississippi. 
 
 
Figure 1.  Structure of phloeodictine class of compounds. 
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This compound was shown to possess potent antifungal activity against the three major 
opportunistic fungal pathogens C. albicans, C. neoformans, and A. fumigatus. Table 2 
shows PHL5-34A compared to amphotericin B. The first half of the table shows the MIC, 
which is the minimum inhibitory concentration against three different fungal organisms. 
This is the lowest concentration that inhibits growth. Amphotericin B has MIC below 2 
µg/ml and PHL5-34A has MIC below 3 µg/ml. Thus, PHL5-34A is comparable in its in vitro 
antifungal activity to amphotericin B. The right side of the table shows the IC50 of the 
two compounds in mammalian cells, which is a measure of their cytotoxicity. The IC50 is 
the concentration that gives 50% inhibition. In this case, the higher the IC50, the lower 
the toxicity levels. As can be seen, PHL5-34A   has an IC50 higher than that of 
amphotericin B showing that it is much less toxic in this laboratory in vitro test.  
Therefore, due to its strong antifungal activity and low toxicity, this marine compound 
was selected for mechanism of action studies in this project.  
Table 2. In vitro Antifungal Activity and Cytotoxicity of PHL5-34A 
  
Antifungal Activity
 
[MIC
a 
(MFC
b
), g/mL] 
  
Cytotoxicity
 
(IC50
c
, 
g/mL) 
 
Compound 
C. albicans C. neoformans A. fumigatus 
 
Vero
d
   
 
HepG2
e 
 
 
PHL5-34ª 2.5 (3.75) 0.47 (0.47) 2.5 (2.5)  26.0   
 
18.5   
 
 
Amphotericin B 0.63 (0.63) 0.94 (1.25) 1.25 (1.25)  7.5   
 
12.0  
 
 
 a 
Minimum Inhibitory Concentration (lowest concentration that allows no detectable growth) 
b 
Minimum Fungicidal Concentration (the lowest  concentration that kills the fungus) 
c 
50% Inhibitory Concentration 
d
African green monkey kidney cells 
e
 Human hepatic carcinoma 
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MATERIALS AND METHODS 
Strains, media, and reagents.  YPD medium (1% yeast extract, 2% peptone, and 2% 
dextrose) was used in all experiments.  The medium was buffered with 0.165 M 3-[N-
Morpholino]propanesulfonic acid (MOPS) and the pH was adjusted with NaOH to 7.0.  
For preparation of agar medium, YPD broth (MOPS buffered, pH 7.0) was aliquoted into 
a glass bottle, agar was added to a final concentration of 2%, and autoclaved at 121C 
for 30 minutes.   The wild-type S. cerevisiae  BY4742 strain and the 166 transcription 
factor mutant strains were obtained from Open Biosystems (Huntsville, AL).  PHL5-34A 
was synthesized at NCNPR, and dimethyl sulfoxide (DMSO) was obtained from Sigma (St. 
Louis, MO).  All stock solutions of PHL5-34A were prepared in DMSO. 
 
Determining drug concentration for mutant screen. A six-well assay was performed to 
determine the drug concentration to be used for screening a collection of S. cerevisiae 
transcription factor mutants. PHL5-34A was added to the YPD (MOPS buffered, pH 7.0) 
agar at different concentrations. The concentrations were as follows: 0 µg/mL, 0.625 
µg/mL, 1.25 µg/mL, 2.5 µg/mL, 5 µg/mL, and 10 µg/mL. The medium was then poured 
into a 6-well plate, and a single colony of the parent yeast strain (BY4742) was streaked 
on each well of the plate. This plate was incubated at 30°C for two days. An image of the 
plate was obtained using the CCD camera available in the Bio-Rad Gel Documentation 
System (Bio-Rad Laboratories, Hercules, CA). 
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Transcription factor mutant screen.  To determine the sensitivity of a collection of 166 
S. cerevisiae transcription factor deletion mutants against PHL5-34A, an agar-based 
screen was conducted.  Each mutant was first streaked from a frozen glycerol stock on 
YPD agar plates containing 200 g/ml of G418 to obtain single colonies.  G418 is an 
antibiotic that allows selective pressure for growth of the mutant strains, and allows 
prevention of contaminant growth by non-mutant strains.  Single colonies of each 
mutant were streaked on YPD (MOPS buffered, pH 7.0) agar plates containing either 
DMSO or 3.0 g/ml PHL5-34A.  At this concentration, PHL5-34A caused partial growth 
inhibition of the parental strain BY4742. One hundred and sixty-six mutants and the 
parental strain BY4742 were streaked on each screening plate using sterile inoculating 
loops.  Plates were incubated at 30°C for 2 days.  Strains were identified that showed a 
marked difference in growth when compared with the parental strain on agar plates 
with PHL5-34A but not on plates with DMSO.  Images of the plates were obtained using 
the Bio-Rad Gel Documentation System. 
 
Confirming PHL5-34A hypersensitivity of 20 transcription factor mutant strains.  To 
confirm the PHL5-34A hypersensitivity of the 20 strains identified in the mutant screen, 
agar-based drop-test assays were performed.  The 20 strains were re-streaked from 
frozen glycerol stocks on YPD + G418 agar plates.  Overnight cultures of each strain were 
started from single colonies in 2 ml of YPD broth (MOPS buffered, pH 7.0) containing 
G418, and incubated at 30C for 22 h.   The parent BY4742 strain was also grown in a 
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similar manner, except no G418 was added to the medium.   The cell density of each 
culture was monitored by measuring the optical density (OD) at 600 nm using a 2100 
Pro UV-Vis Spectrophotometer (GE Healthcare, Piscataway, NJ).  Each culture was then 
diluted to an OD600 of 3.0 in YPD broth (MOPS buffered, pH 7.0).  From this diluted 
culture, 1:5 serial dilutions were prepared in the same medium, resulting in 6 total 
dilutions.  Cells from each dilution were then spotted in 3 l amounts on YPD agar plates 
+/- 3.0 g/ml PHL5-34A.  Plates were incubated for 2 days at 30°C.  Images of the plates 
were obtained using the Bio-Rad Gel Documentation System. 
 
PCR confirmation of 4 transcription factor mutant strains. Deletion mutant strains 
were streaked for single colonies on YPD + G418 plates. Colony PCR was performed by 
denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 sec, 
annealing at 55°C for 30 sec, and extension at 72°C for 1 min.  Platinum Taq DNA 
Polymerase (Invitrogen Corporation), a hot-start enzyme, was utilized in all reactions to 
increase specificity and sensitivity. Each PCR reaction was analyzed by agarose gel 
electrophoresis, and an image of the gel was obtained using the Bio-Rad Gel 
Documentation System. Each deletion mutant was confirmed using the “A,” “B,” “C,” 
“D,” “KanB,” and “KanC” primers as described on the Saccharomyces Genome Deletion 
Project (http://www-
sequence.stanford.edu/group/yeast_deletion_project/deletions3.html).  The "A" and 
"D" primers are located upstream and downstream of the coding region respectively, 
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while the "B" and "C" primers are located within the coding region.  The "KanB" and 
"KanC" primers are located in the KanMX gene used to replace the target gene in each 
deletion strain.  PCR products are obtained in the “A”/ “KanB” and “D”/ “KanC” primer 
combinations, while the “A”/ “B” and “C”/ “D” primer combinations result in no PCR 
products. 
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RESULTS AND DISCUSSION 
 
Strategy for evaluating the MOA of PHL5-34A.  The strategy for evaluating the 
mechanism of action (MOA) of PHL5-34A was to identify hypersensitive mutants from a 
collection of yeast mutants that have deletions in transcription factors. The deleted 
genes in the mutants provide clues about the MOA of the drug. Using deletion mutants 
in a MOA study is an important strategy. For example, ketoconazole is an antifungal 
drug that inhibits ergosterol biosynthesis by targeting the ERG11 gene in the ergosterol 
synthesis pathway. If a normal wild type cell is treated with ketoconazole, it will show 
sensitivity to ketoconazole since the pathway will be inhibited at the step catalyzed by 
ERG11. If there is a deletion in the ERG8 gene, which catalyzes a step upstream of the 
ERG11 step, this mutant (erg8) will show hypersensitivity to ketoconazole because the 
pathway will be inhibited at two steps in this mutant (Hillenmeyer et al., 2008). 
Similarly, a mutant with deletion in the ERG9 gene (erg9), and a mutant with a deletion 
in the ERG4 gene (erg4), both of which catalyze various steps in the pathway, is 
hypersensitive to ketoconazole (Hillenmeyer et al., 2008). Thus, if a novel antifungal 
compound is identified and if erg11, erg8, erg9, and erg4 mutants are 
hypersensitive to it, then that would suggest that the novel compound is an ergosterol 
synthesis inhibitor. 
 
Using mutants with deletions in transcription factors is also an important strategy in 
MOA studies.  A transcription factor is a protein that binds to a specific DNA sequence in 
 23 
 
a gene and regulates its expression. For example, Upc2 is a transcription factor that 
regulates the expression of the ERG11 gene (Vik and Rine, 2001).  Upc2 also regulates 
several other ergosterol synthesis genes (e.g., ERG2, ERG3, ERG9, ERG10, ERG24, 
ERG26) making Upc2 a master regulator of genes involved in ergosterol biosynthesis 
(Teixeira et al., 2006). Interestingly, the Upc2 deletion mutant is hypersensitive to 
ketoconazole (Agarwal et al., 2003).  Thus, if a novel antifungal compound is identified 
and if upc2 mutant is hypersensitive to it, then that would suggest that the novel 
compound is an ergosterol inhibitor.  In MOA studies, one can analyze the Upc2 
transcription factor mutant instead of all of the mutants with deletions in individual 
ergosterol synthesis genes. 
 
Determining drug concentration for the mutant screen.  First, an experiment in a six-
well assay was used to determine the drug concentration to be used in the mutant 
screen. PHL5-34A was added to YPD agar at different concentrations. A no-drug control 
was included which consisted of 1% DMSO since DMSO was the solvent used to dissolve 
the drug.  The medium was then poured into a 6-well plate, and the parent yeast strain 
was spread on the medium. The plate was incubated at 30C for two days, and 
photographs were taken after the incubation period. As can be seen in Figure 2, the left 
bottom well did not have any drug, and as you move to the right and up, the drug 
concentration increased. If the growth of the yeast cells is observed, there is maximum 
growth without drug, and the growth decreases as the drug concentration increases. 
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Based on this assay, 3 µg/ml was chosen as the drug concentration because at this sub-
inhibitory concentration, cell growth would be inhibited, but not very severely. 
 
 
 
 
 
 
 
 
 
Figure 2.  Determining PHL5-34A concentration for the mutant screen.  A 6-well assay was 
performed at various concentrations of PHL5-34A using the parent strain.  Image taken after 2 
days of incubation is shown. 
 
 
Transcription factor mutant screen.  Once the drug concentration was determined, a 
collection of 166 yeast mutants with deletions in transcription factors was screened 
against PHL5-34A. PHL5-34A was added to agar at a concentration of 3 µg/ml, and 1% 
DMSO was added to the agar as a control. The medium was then poured into 
petriplates, the parent and the 166 yeast mutant strain was spread onto the plates. 
These plates were then incubated at 30°C for two days. With this screen of 166 yeast 
mutants, twenty mutants were identified as hypersensitive.  Figure 3 shows images of 4 
representative mutants that were hypersensitive to PHL5-34A. 
 25 
 
                                                
Figure 3.  Transcription factor mutant screen.  A screen was performed at 3µg/ml concentration 
of PHL5-34A against 166 yeast mutants.  Images taken after 2 days of incubation are shown.  
The images show four representative mutants that were hypersensitive to PHL5-34A. 
 
 
Confirming PHL5-34A hypersensitivity of 20 transcription factor mutant strains. After 
the initial screen, a confirmation test of the twenty hypersensitive mutants was 
conducted because the initial screen may give false positives. A false positive in the 
initial screen is a possibility because the cell density was not controlled in the initial 
screen. The mutant was grown onto a petriplate, and a single colony was inoculated 
onto the drug-containing petriplate to test for hypersensitivity.  Thus, a mutant may 
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incorrectly appear to be hypersensitive if the colony was small in size or if there were 
not enough cells present in a colony.  On the other hand, in the confirmation test, the 
density of cells was controlled by taking an OD of the cells in the sample colony, and 
each culture was diluted to an OD of 3.0.  Thus, the same number of cells were present 
for all mutant strains, including the parent strain. 
 
The parent as well as the twenty hypersensitive mutants were analyzed by drop test 
assays. This was done by serial dilutions of the cells, and 3 µL drops of each dilution 
were placed on the medium. The plates were then incubated at 30°C for two days. Of 
the twenty mutants that were identified, ten were confirmed through the drop test 
assay to have hypersensitivity to PHL5-34A (Figure 4). Of the ten confirmed mutants, 
four mutants have deletions in genes that are required for cell cycle regulation.  ACE2, 
SWI6, UME6, and MBP1 were the four genes in these mutants that play a role in cell 
cycle function (based on Saccharomyces Genome Database). ACE2 is a gene that is 
responsible for the regulation of transcription during the G1 phase of mitotic cell cycle. 
SWI6 is responsible for the regulation of transcription of the G1 and S phase of mitotic 
cell cycle. The gene UME6 is responsible for reciprocal mitotic recombination, and MBP1 
is a gene that is responsible for the regulation of cell cycle.  The remaining six mutants 
carried deletions in genes that were not of interest because their pathways did not 
show any specific patterns in their functions.  
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These results suggest that the cell cycle may be one of the pathways targeted by PHL5-
34A.  This result is in agreement with a previous mutant assay study conducted on 
another phloeodictine analog synthesized at the NCNPR.  In that study, out of 67 
mutants identified from a collection of ~5000 mutants, 9 were involved in cell cycle 
functions.   
 
 
 
 
Figure 4.  Confirming PHL5-34A hypersensitivity of 20 transcription factor mutant strains.  A 
screen was performed to confirm the twenty hypersensitive mutants from the initial screen. Ten 
of the twenty hypersensitive mutants from the initial screen confirmed.  Image taken after 2 
days of incubation is shown.  Mutants with deletions in cell cycle genes are shown in red. 
 
PCR confirmation of 4 transcription factor mutant strains.  A polymerase chain reaction 
(PCR) was performed on the four transcription factor mutant strains that contained 
deletions in cell cycle genes.  The purpose of the PCR analysis was to confirm that the 
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mutant strains carried deletions in the correct genes. The deletion mutant strains that 
were used in this project were purchased from a commercial vendor, so there is 
possibility that errors may occur in the designation of the mutants. 
 
The four strains under study were streaked onto agar plates to get single colonies. The 
PCR reactions were performed on a single colony for each strain using the appropriate 
primer conditions. The PCR reactions were then analyzed by agarose gel 
electrophoresis.  As shown in Figure 5, in the normal ACE2 gene, the ORF or Open 
Reading Frame is in the middle, and the 5’ and 3’ regions are at the ends. In the deleted 
ACE2 gene, the ACE2 ORF is replaced with the KanMx ORF. Primers are designed to 
correspond to the appropriate regions in the gene. For example, in the ACE2 deletion 
mutant, with the ACE2-A and ACE2-B primers, we should get no PCR product. Similarly, 
ACE2-C and ACE2-D primers give no PCR product. But ACE2-A and KanB primers will give 
a PCR product, and also ACE2-D and KanC will give a PCR product.  
 
 
 
Figure 5.  Expected PCR results for ace2 mutant.  The diagram on the left shows the positions 
of the primers in the normal and deleted ACE2 gene.  The table on the right shows the expected 
PCR results. 
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PCR reactions on all four mutants were conducted, and in each case, PCR products were 
not visible with A+B and C+D primer. But PCR products were visible with A+KanB and 
D+KanC primers.  All of the mutants gave the expected PCR products (Figure 6), and the 
mutants were confirmed to carry deletions in the correct genes. 
 
 
 
           
 
 
Figure 6.  PCR confirmation of 4 transcription factor mutant strains. PCR analysis was 
performed to confirm that the four hypersensitive mutants carried deletions in the correct 
genes. Image taken after the agarose gel electrophoresis was completed is shown.  
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CONCLUSIONS 
In this project, a MOA study was conducted on the novel antifungal compound, PHL5-
34A, using a collection of yeast mutants that contained deletions in transcription 
factors.  A screen of this type identifies mutants that are hypersensitive to a novel 
compound, and the genes deleted in those mutants provide clues about the pathways 
targeted by the compound.  Of the 166 mutants that were screened in this study, ten 
confirmed mutants showed hypersensitivity to PHL5-34A.  Interestingly, four of these 
ten mutants carried deletions in cell cycle genes. This suggests that cell cycle is one of 
the pathways targeted by PHL5-34A. While there are several anticancer drugs such as 
Taxol that target the cell cycle (Gascoigne and Taylor, 2009), the current antifungal 
drugs don’t inhibit cell cycle.  Thus, this a potentially novel antifungal target for new 
drug discovery. Given the central role played by the cell cycle in cell division and growth, 
inhibiting the cell cycle will have a dramatic effect on cell viability.   On the other hand, 
since the cell cycle is an important process in all eukaryotic cells, it is possible that PHL5-
34A may cause an inhibitory effect on not only fungal cells but also on the human host 
cells.  However, the in vitro cytotoxicity studies on PHL5-34A indicate that it has low 
inhibitory activity against mammalian cells (see Table 2) – thus, it may target specific 
aspects of the fungal cell cycle.  In addition, PHL5-34A may serve as an important tool in 
further exploring how the fungal cell cycle is regulated.  In conclusion, this study 
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indicates that PHL5-34A may target the cell cycle, and it provides a useful starting point 
for further studies to determine the precise MOA of this class of compounds. 
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